BIOMAT Database Logo BIOMAT Database Logo

Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine Sulfonamides as an Important Scaffold for Anticancer Drug Discovery-In Vitro and In Silico Evaluation. 2023

Mateusz Kciuk, and Beata Marciniak, and Ismail Celik, and Enfale Zerroug, and Amit Dubey, and Rajamanikandan Sundaraj, and Somdutt Mujwar, and Karol Bukowski, and Mariusz Mojzych, and Renata Kontek
Department of Molecular Biotechnology and Genetics, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.

Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulfonamides (MM-compounds) are a relatively new class of heterocyclic compounds that exhibit a wide variety of biological actions, including anticancer properties. Here, we used caspase enzyme activity assays, flow cytometry analysis of propidium iodide (PI)-stained cells, and a DNA laddering assay to investigate the mechanisms of cell death triggered by the MM-compounds (MM134, -6, -7, and -9). Due to inconsistent results in caspase activity assays, we have performed a bromodeoxyuridine (BrdU) incorporation assay, colony formation assay, and gene expression profiling. The compounds' cytotoxic and pro-oxidative properties were also assessed. Additionally, computational studies were performed to demonstrate the potential of the scaffold for future drug discovery endeavors. MM-compounds exhibited strong micromolar (0.06-0.35 µM) anti-proliferative and pro-oxidative activity in two cancer cell lines (BxPC-3 and PC-3). Activation of caspase 3/7 was observed following a 24-h treatment of BxPC-3 cells with IC50 concentrations of MM134, -6, and -9 compounds. However, no DNA fragmentation characteristics for apoptosis were observed in the flow cytometry and DNA laddering analysis. Gene expression data indicated up-regulation of BCL10, GADD45A, RIPK2, TNF, TNFRSF10B, and TNFRSF1A (TNF-R1) following treatment of cells with the MM134 compound. Moreover, in silico studies indicated AKT2 kinase as the primary target of compounds. MM-compounds exhibit strong cytotoxic activity with pro-oxidative, pro-apoptotic, and possibly pro-necroptotic properties that could be employed for further drug discovery approaches.

UI MeSH Term Description Entries
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D000077145 Sulfanilamide A short-acting sulfonamide used as an anti-infective agent. It has lower anti-bacterial activity than SULFAMETHOXAZOLE. 4-aminobenzenesulfonamide,Azol Polvo,Sulfanilamide Barium Salt,Sulfanilamide Cadmium Salt,Sulfanilamide Hydrochloride,Sulfanilamide Lithium Salt,Sulfanilamide Magnesium Salt,Sulfanilamide Monohydrate,Sulfanilamide Silver Salt,Sulfanilamide Sodium,Sulfanilamide Sodium Salt,Sulfanilamide Strontium Salt,Sulfanilamide Zinc Salt,Sulphanilamide,4 aminobenzenesulfonamide
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D014227 Triazines Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES. Triazine,Benzotriazines
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Mateusz Kciuk, and Beata Marciniak, and Ismail Celik, and Enfale Zerroug, and Amit Dubey, and Rajamanikandan Sundaraj, and Somdutt Mujwar, and Karol Bukowski, and Mariusz Mojzych, and Renata Kontek
The activity of pyrazolo[4,3-e][1,2,4]triazine and pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulphonamide derivatives in monolayer and spheroid breast cancer cell cultures.
December 2024, Journal of enzyme inhibition and medicinal chemistry,
Mateusz Kciuk, and Beata Marciniak, and Ismail Celik, and Enfale Zerroug, and Amit Dubey, and Rajamanikandan Sundaraj, and Somdutt Mujwar, and Karol Bukowski, and Mariusz Mojzych, and Renata Kontek
New pyrazolo[4,3-e][1,2,4]triazine sulfonamides as carbonic anhydrase inhibitors.
July 2015, Bioorganic & medicinal chemistry,
Mateusz Kciuk, and Beata Marciniak, and Ismail Celik, and Enfale Zerroug, and Amit Dubey, and Rajamanikandan Sundaraj, and Somdutt Mujwar, and Karol Bukowski, and Mariusz Mojzych, and Renata Kontek
Pyrazolo[4,3-e][1,2,4]triazine sulfonamides as carbonic anhydrase inhibitors with antitumor activity.
May 2014, Bioorganic & medicinal chemistry,
Mateusz Kciuk, and Beata Marciniak, and Ismail Celik, and Enfale Zerroug, and Amit Dubey, and Rajamanikandan Sundaraj, and Somdutt Mujwar, and Karol Bukowski, and Mariusz Mojzych, and Renata Kontek
Synthesis of chiral pyrazolo[4,3-e][1,2,4]triazine sulfonamides with tyrosinase and urease inhibitory activity.
December 2017, Journal of enzyme inhibition and medicinal chemistry,
Mateusz Kciuk, and Beata Marciniak, and Ismail Celik, and Enfale Zerroug, and Amit Dubey, and Rajamanikandan Sundaraj, and Somdutt Mujwar, and Karol Bukowski, and Mariusz Mojzych, and Renata Kontek
Review of the Synthesis and Anticancer Properties of Pyrazolo[4,3-e][1,2,4]triazine Derivatives.
August 2020, Molecules (Basel, Switzerland),
Mateusz Kciuk, and Beata Marciniak, and Ismail Celik, and Enfale Zerroug, and Amit Dubey, and Rajamanikandan Sundaraj, and Somdutt Mujwar, and Karol Bukowski, and Mariusz Mojzych, and Renata Kontek
Synthesis of pyrazolo[4,3-e][1,2,4]triazine sulfonamides, novel Sildenafil analogs with tyrosinase inhibitory activity.
December 2014, Bioorganic & medicinal chemistry,
Mateusz Kciuk, and Beata Marciniak, and Ismail Celik, and Enfale Zerroug, and Amit Dubey, and Rajamanikandan Sundaraj, and Somdutt Mujwar, and Karol Bukowski, and Mariusz Mojzych, and Renata Kontek
1,3-Dimethyl-5-methyl-sulfonyl-1H-pyrazolo-[4,3-e][1,2,4]triazine.
November 2010, Acta crystallographica. Section E, Structure reports online,
Mateusz Kciuk, and Beata Marciniak, and Ismail Celik, and Enfale Zerroug, and Amit Dubey, and Rajamanikandan Sundaraj, and Somdutt Mujwar, and Karol Bukowski, and Mariusz Mojzych, and Renata Kontek
Synthesis and pharmacological evaluation of 6,8-diaryl 1,2,4-triazolo [4,3,-b] and 1,2,3,4,-tetrazolo [1,5-b] pyridazines.
March 1990, Farmaco (Societa chimica italiana : 1989),
Mateusz Kciuk, and Beata Marciniak, and Ismail Celik, and Enfale Zerroug, and Amit Dubey, and Rajamanikandan Sundaraj, and Somdutt Mujwar, and Karol Bukowski, and Mariusz Mojzych, and Renata Kontek
Synthesis, biological evaluation, and in silico studies of new CDK2 inhibitors based on pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold with apoptotic activity.
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Mateusz Kciuk, and Beata Marciniak, and Ismail Celik, and Enfale Zerroug, and Amit Dubey, and Rajamanikandan Sundaraj, and Somdutt Mujwar, and Karol Bukowski, and Mariusz Mojzych, and Renata Kontek
Synthesis, Structure and Antiproliferative Activity of New pyrazolo[4,3- e]triazolo[4,5-b][1,2,4]triazine Derivatives.
January 2018, Medicinal chemistry (Shariqah (United Arab Emirates)),
Copied contents to your clipboard!